Northwest Biotherapeutics, Inc.
NWBO
$0.214
$0.00170.80%
| Weiss Ratings | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.39 | |||
| Price History | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.83% | |||
| 30-Day Total Return | -14.37% | |||
| 60-Day Total Return | -23.54% | |||
| 90-Day Total Return | -21.32% | |||
| Year to Date Total Return | -22.01% | |||
| 1-Year Total Return | -60.88% | |||
| 2-Year Total Return | -64.53% | |||
| 3-Year Total Return | -69.54% | |||
| 5-Year Total Return | 35.53% | |||
| 52-Week High % Change | -62.75% | |||
| 52-Week Low % Change | 8.87% | |||
| Price | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.57 | |||
| 52-Week Low Price | $0.20 | |||
| 52-Week Low Price (Date) | Apr 01, 2025 | |||
| 52-Week High Price (Date) | Apr 08, 2024 | |||
| Valuation | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 287.99M | |||
| Enterprise Value | 368.76M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.08 | |||
| Earnings Per Share Growth | 11.30% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 176.92 | |||
| Price/Book (Q) | -3.41 | |||
| Enterprise Value/Revenue (TTM) | 231.05 | |||
| Price | $0.21 | |||
| Enterprise Value/EBITDA (TTM) | -6.00 | |||
| Enterprise Value/EBIT | -5.84 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.26B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 240 497 9024 | |||
| Address | 4800 Montgomery Lane Bethesda, MD 20814 | |||
| Website | www.nwbio.com | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -3,956.82% | |||
| Profit Margin | -4,666.29% | |||
| Management Effectiveness | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -129.81% | |||
| Return on Equity | -- | |||
| Income Statement | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.60M | |||
| Total Revenue (TTM) | 1.60M | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -30.22M | |||
| EBITDA (TTM) | -61.42M | |||
| EBIT (TTM) | -63.15M | |||
| Net Income (TTM) | -74.47M | |||
| Net Income Avl. to Common (TTM) | -74.47M | |||
| Total Revenue Growth (Q YOY) | -12.07% | |||
| Earnings Growth (Q YOY) | 17.63% | |||
| EPS Diluted (TTM) | -0.08 | |||
| EPS Diluted Growth (Q YOY) | 5.66% | |||
| Balance Sheet | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.94M | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 5.19M | |||
| Total Preferred Equity (Q) | 15.88 | |||
| Total Equity (Q) | -64.24M | |||
| Current Ratio (Q) | 0.087 | |||
| Book Value Per Share (Q) | -$0.06 | |||
| Total Assets (Q) | 29.32M | |||
| Total Current Liabilities (Q) | 59.56M | |||
| Total Debt (Q) | 58.34M | |||
| Total Liabilities (Q) | 93.56M | |||
| Total Common Equity (Q) | -80.12M | |||
| Cash Flow | NWBO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.35M | |||
| Cash from Financing (TTM) | 55.26M | |||
| Net Change in Cash (TTM) | -3.16M | |||
| Levered Free Cash Flow (TTM) | -32.72M | |||
| Cash from Operations (TTM) | -53.79M | |||
